GlassScriptPhysician profile
Erin Borns
NPI 1639562630
$2,532.82
in general payments reported to CMS, 2019-2025
38 companies · $615 in 2025
The $615 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $534 · 2022: $483 · 2023: $578 · 2024: $324 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,421 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,421.08 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $382.36 | 2021-2025 | Farxiga, Fasenra, Bevespi Aerosphere |
| Abbvie INC. | $374.01 | 2021-2024 | |
| Novo Nordisk INC | $294.56 | 2021-2023 | Ozempic, Rybelsus |
| Pfizer INC. | $154.97 | 2022-2025 | |
| Adaptive Biotechnologies Corporation | $139.57 | 2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2022 | |
| Aveo Pharmaceuticals, INC. | $94.99 | 2024 | |
| Karyopharm Therapeutics INC. | $87.59 | 2024-2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $80.19 | 2021-2022 | |
| Lilly USA, LLC | $53.74 | 2021-2023 | Mounjaro |
| Genentech USA, INC. | $53.45 | 2021-2025 | Venclexta, Tecentriq |
| Eisai INC. | $51.00 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $48.39 | 2025 | |
| Daiichi Sankyo INC. | $44.25 | 2025 | Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $40.94 | 2021-2024 | Iclusig |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Borns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.